{
    "info": {
        "nct_id": "NCT04829383",
        "official_title": "A Phase II Study of Atezolizumab and Bevacizumab in Child-Pugh B7 and B8 Hepatocellular Carcinoma (The AB7 Trial)",
        "inclusion_criteria": "Subject must meet all of the following applicable inclusion criteria to participate in this study:\n\n* Written informed consent and HIPAA authorization for release of personal health information must be obtained either from the subject or their representative. See protocol. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.\n* Age ≥ 18 years at the time of consent.\n* ECOG Performance Status of 0-1.\n* Locally advanced, metastatic, or unresectable hepatocellular carcinoma that has not received prior systemic therapy. Note: if no prior histologic diagnosis exists, prefer fresh biopsy if it is both safe and feasible. If fresh biopsy is not safe and feasible, imaging criteria may be used for diagnosis as per AASLD criteria in cirrhotic patients (please see www.aasld.org for up to date guidelines).\n* Child Pugh Class B7 or B8 liver dysfunction or cirrhosis with the following limitations:\n\n  * Bilirubin ≤ 3 mg/dL\n  * Albumin ≥ 2.8 g/dL\n  * INR ≤ 1.7\n  * Absent to slight [CP=1 to 2] (no moderate [CP=3]) ascites (Also see exclusion criteria).\n  * No clinically significant encephalopathy (Also see exclusion criteria).\n* At least 1 untreated measurable lesion according to RECIST 1.1.\n* Willingness to undergo fresh tumor biopsy at baseline if safe and feasible. Note: archival tissue may be used at baseline provided histologic diagnosis was made and sufficient tissue is available for NGS analysis.\n* NGS analysis must be requested from archival tissue or fresh biopsy (if applicable) as per standard of care. Foundation One CDX is the preferred platform. Prior NGS sequencing results (including from another platform) will be accepted if NGS sequencing was previously obtained (please see protocol).\n* Demonstrate adequate bone marrow and organ function as defined below:\n\n  * Hematologic\n\n    * Absolute neutrophil count (ANC) ≥ 1,000/mcL\n    * Lymphocyte count ≥ 0.5 x 10^9/L (500uL)\n    * Hemoglobin ≥ 90 g/L (9 g/dL)\n    * Platelet count ≥ 70,000/mcL\n  * Renal\n\n    * Serum creatinine OR calculated* serum creatinine clearance (GFR can be used in place of creatinine or creatinine clearance) ≤ 1.5 x ULN OR ≥ 30 mL/min for participants with creatinine levels > 1.5 x institutional ULN *calculate serum creatinine clearance using the standard Coccroft-Gault formula\n    * Urine protein: Urine dipstick for proteinuria < 2+ within 7 days prior to start of study treatment *Patients with with ≥ 2+ proteinuria on dipstick analysis at baseline should undergo a 24-hour urine collection which must demonstrate < 1g of protein in 24 hours.\n  * Hepatic\n\n    * AST (SGOT) and ALT (SGPT) ≤ 8 x ULN\n    * Alkaline phosphastase (ALP) ≤ 8 x ULN\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, or 6 months after the last dose of bevacizumab. See also the protocol for definition of childbearing potential.\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use effective contraceptive measures. Men with female partners of childbearing potential must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of bevacizumab. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab to avoid exposing the embryo. See also the protocol for additional information.\n* As determined by the enrolling physician or protocol designee, ability of the subject to understand a written informed consent document, and ability and willingness to comply with study procedures for the entire length of the study. Patients with impaired decision-making capacity (IDMC) who have a close caregiver or legally authorized representative (LAR) and/or family member available are also eligible.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Subjects meeting any of the criteria below may not participate in the study:\n\n* Histologic diagnosis of fibrolamellar or sarcomatoid HCC or mixed cholangiocarcinoma-HCC.\n* Patients who have had chemotherapy, definitive radiation, biological cancer therapy, or investigational agent/device within 21 days of first planned dose of study therapy (within 14 days for palliative radiation). Patients who have had major surgery within 4 weeks of start of study therapy or anticipation of need for a major surgical procedure during the study.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > CTCAE Grade 1) with the exception of alopecia or neuropathy.\n* Patients who have received prior systemic therapy for HCC.\n* Patients who have received prior immunotherapy.\n* Patients with clinically meaningful ascites, defined as ascites requiring non-pharmacologic intervention (e.g. paracentesis) to maintain symptomatic control within 3 months prior to the first dose of study treatment. Note: Patients with ascites meeting eligibility criteria who require pharmacologic intervention (e.g. diuretics) to maintain symptomatic control and who have been on stable doses of diuretics for 2 months prior to the first dose of study treatment are eligible.\n* Patients with clinically meaningful encephalopathy, defined as a history of hepatic encephalopathy within 6 months prior to first dose of study treatment or requirement for medications to prevent or control encephalopathy (e.g. lactulose, rifaximin).\n* Any of the following additional high-risk features:\n\n  * Patients with untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Note: Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD with appropriate management of varices (if applicable) within 6 months of prior to initiation of study treatment do not need to repeat the procedure.\n  * History of esophageal and/or gastric hemorrhage within 3 months prior to study treatment.\n  * History of hemoptysis (< 2.5 mL of bright red blood per episode) within 1 month prior to study treatment.\n  * History of intracranial hemorrhage within 1 month prior to study treatment.\n  * History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment. Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure.\n  * Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture within 30 days prior to start of study treatment.\n  * Metastatic disease that involves major airways or blood vessels. Patients with vascular invasion of the portal or hepatic veins may be enrolled.\n  * Significant vascular disease (e.g. aortic aneurysm requiring surgical repair) or vasculitis within 6 months prior to initiation of study treatment.\n  * History of arterial thrombotic event (e.g. myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack) within 6 months prior to initiation of study treatment.\n  * Chronic or recent (within 10 days of first dose of study treatment) use of aspirin > 325 mg/day, dipyramidaole, ticlopidine, clopidogrel, or dilostazol. Note: Use of aspirin < 325 mg/day is allowed.\n  * History of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary embolism, portal vein thrombosis, or any other significant thromboembolism) must be on a stable dose of anticoagulation for 1 month prior to initiation of study treatment and must have completely treated varices.\n  * Use of Coumadin-like products or full dose oral or parenteral anticoagulants. Use of prophylactic low dose anticoagulation, unfractionated heparin or LMWH is allowed.\n  * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).\n  * Core biopsy or other minor surgical procedure within 3 days prior to the first dose of bevacizumab.\n  * History of intestinal obstruction. Note: Patients with previous intestinal obstruction may be enrolled if they have received definitive treatment for symptom resolution.\n  * History of inflammatory process within 6 months prior to start of study treatment including but not limited to active peptic ulcer disease, diverticulitis or colitis.\n  * Significant traumatic injury within 4 weeks prior to start of study treatment.\n  * Uncontrolled pleural effusion or pericardial effusion requiring frequent drainage procedures (> once monthly). Patients with indwelling catheters (e.g. PleurX®) are allowed.\n  * History of nephrotic or nephritic syndrome.\n  * Uncontrolled hypertension defined as systolic pressure ≥ 150/90 in spite of maximum anti-hypertensive therapy.\n* Patients with untreated/uncontrolled CNS/leptomeningeal disease. Note: Patients with asymptomatic, treated CNS disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy and the following criteria are met:\n\n  * No evidence of interim progression between the completion of CNS-directed therapy and the start of study enrollment.\n  * No stereotactic radiation or whole-brain radiation within 28 days prior to randomization.\n  * No evidence of intracranial hemorrhage or spinal cord hemorrhage.\n* Patients with active autoimmune disease requiring systemic corticosteroids greater than the equivalent of prednisone 10 mg daily or other systemic immunosuppressive medications including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, colitis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis, with the following exceptions:\n\n  * Patients with a history of autoimmune hypothyroidism on thyroid replacement hormone are eligible.\n  * Patients with Type 1 diabetes mellitus on an insulin regimen are eligible.\n  * Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only are eligible provided: 1) rash covers < 10% of body surface area (BSA), 2) disease is well controlled at baseline and requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%).\n  * See protocol for a more comprehensive list of autoimmune diseases and immune deficiencies.\n* Patients receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 6 weeks must discontinue these medications prior to starting protocol therapy, with the exception of:\n\n  * Patients with active autoimmune disease managed with systemic corticosteroids less than the equivalent of prednisone 10 mg daily.\n  * Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).\n  * The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension and adrenocortical insufficiency.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Patients who have undergone prior solid organ or bone marrow transplant with the exception of patients with prior renal transplant for whom dialysis may be employed in the event of graft rejection.\n* Patients with serious active infection within 2 weeks prior to enrollment (e.g. requiring hospitalization and/or intravenous [IV] antibiotics) infection within 2 weeks prior to enrollment, or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible.\n* Patients must have documented hepatitis virology status.\n\n  * Patients with active hepatitis B virus (HBV) infection must have a viral load < 500 IU/mL within 28 days prior to start of study treatment and be on suppressive therapy (per local standard of care) for a minimum of 14 days prior to start of study treatment and for the length of the study.\n  * Patients with co-infection with HBV and hepatitis C virus (HCV) are excluded. Patients with a history of HCV infection but with negative HCV RNA by PCR are considered non-infected with HCV.\n* Patients with known human immunodeficiency virus (HIV) are allowed on study provided they have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent concurrent antibiotics or antifungal agents for the prevention of opportunistic infection\n  * A CD4 count above 250 cells/mcL\n  * An undetectable HIV viral load on standard PCR-based testing\n* Patients with uncontrolled intercurrent illness (e.g., including but not limited to uncontrolled HTN [systolic BP ≥ 150, diastolic BP ≥ 100 despite optimal medical management or history of hypertensive crisis or hypertensive encephalopathy], symptomatic congestive heart failure [CHF], uncontrolled cardiac arrhythmia, or other within 3 months prior to start of study treatment or psychiatric illness/social situations or other conditions that would limit compliance with study requirements or substantially increase risk of incurring AEs in the opinion of the treating investigator.\n* Patients with known concurrent malignancy that is expected to require active treatment within two years or may interfere with the interpretation of the efficacy and safety outcomes of this study in the opinion of the treating investigator. Note: Superficial bladder cancer, nonmelanoma skin cancers, and low-grade prostate cancer not requiring cytotoxic therapy should not exclude participation in this trial. Patients with CLL may be enrolled if they do not require active chemotherapy and their hematologic, renal and hepatic function meets criteria previously mentioned.\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications in the opinion of the treating investigator.\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment.\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins or know hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab infusion.\n* Uncontrolled tumor-related pain. NOTE: Patients requiring pain medication must be on a stable regimen at study entry.\n\nSymptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.\n\n* Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)\n* Active tuberculosis\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* INR ≤ 1.7",
            "criterions": [
                {
                    "exact_snippets": "INR ≤ 1.7",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.7,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alkaline phosphastase (ALP) ≤ 8 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alkaline phosphastase (ALP) ≤ 8 x ULN",
                    "criterion": "alkaline phosphatase (ALP) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18 years at the time of consent.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years at the time of consent.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin ≤ 3 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 3 mg/dL",
                    "criterion": "bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Written informed consent and HIPAA authorization for release of personal health information must be obtained either from the subject or their representative. See protocol. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent ... must be obtained either from the subject or their representative.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIPAA authorization for release of personal health information must be obtained either from the subject or their representative.",
                    "criterion": "HIPAA authorization for release of personal health information",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 70,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 70,000/mcL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absent to slight [CP=1 to 2] (no moderate [CP=3]) ascites (Also see exclusion criteria).",
            "criterions": [
                {
                    "exact_snippets": "Absent to slight [CP=1 to 2] (no moderate [CP=3]) ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "CP"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "CP"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "severity_exclusion",
                            "expected_value": {
                                "operator": "!=",
                                "value": 3,
                                "unit": "CP"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 90 g/L (9 g/dL)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 90 g/L (9 g/dL)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematologic",
            "criterions": [
                {
                    "exact_snippets": "Hematologic",
                    "criterion": "hematologic status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "hematologic status is evaluated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatic",
            "criterions": [
                {
                    "exact_snippets": "Hepatic",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Demonstrate adequate bone marrow and organ function as defined below:",
            "criterions": [
                {
                    "exact_snippets": "Demonstrate adequate bone marrow ... function",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Demonstrate adequate ... organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Child Pugh Class B7 or B8 liver dysfunction or cirrhosis with the following limitations:",
            "criterions": [
                {
                    "exact_snippets": "Child Pugh Class B7 or B8 liver dysfunction",
                    "criterion": "Child Pugh class",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "B7",
                                "B8"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cirrhosis",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least 1 untreated measurable lesion according to RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 untreated measurable lesion according to RECIST 1.1.",
                    "criterion": "measurable lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "according to RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lymphocyte count ≥ 0.5 x 10^9/L (500uL)",
            "criterions": [
                {
                    "exact_snippets": "Lymphocyte count ≥ 0.5 x 10^9/L (500uL)",
                    "criterion": "lymphocyte count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "x 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG Performance Status of 0-1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG Performance Status of 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urine protein: Urine dipstick for proteinuria < 2+ within 7 days prior to start of study treatment *Patients with with ≥ 2+ proteinuria on dipstick analysis at baseline should undergo a 24-hour urine collection which must demonstrate < 1g of protein in 24 hours.",
            "criterions": [
                {
                    "exact_snippets": "Urine dipstick for proteinuria < 2+ within 7 days prior to start of study treatment",
                    "criterion": "urine protein (proteinuria) by dipstick",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to start of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with ... ≥ 2+ proteinuria on dipstick analysis at baseline should undergo a 24-hour urine collection which must demonstrate < 1g of protein in 24 hours",
                    "criterion": "urine protein (proteinuria) by 24-hour urine collection",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "g"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "24 hours"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, or 6 months after the last dose of bevacizumab. See also the protocol for definition of childbearing potential.",
            "criterions": [
                {
                    "exact_snippets": "For women of childbearing potential",
                    "criterion": "childbearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, or 6 months after the last dose of bevacizumab",
                    "criterion": "contraception or abstinence",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive method failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "contraception or abstinence duration after last dose of atezolizumab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "contraception or abstinence duration after last dose of bevacizumab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Locally advanced, metastatic, or unresectable hepatocellular carcinoma that has not received prior systemic therapy. Note: if no prior histologic diagnosis exists, prefer fresh biopsy if it is both safe and feasible. If fresh biopsy is not safe and feasible, imaging criteria may be used for diagnosis as per AASLD criteria in cirrhotic patients (please see www.aasld.org for up to date guidelines).",
            "criterions": [
                {
                    "exact_snippets": "Locally advanced, metastatic, or unresectable hepatocellular carcinoma",
                    "criterion": "hepatocellular carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic",
                                "unresectable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "has not received prior systemic therapy",
                    "criterion": "prior systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "if no prior histologic diagnosis exists, prefer fresh biopsy if it is both safe and feasible. If fresh biopsy is not safe and feasible, imaging criteria may be used for diagnosis as per AASLD criteria in cirrhotic patients",
                    "criterion": "diagnosis method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologic diagnosis",
                                "fresh biopsy (if safe and feasible)",
                                "imaging criteria (AASLD, if biopsy not safe/feasible)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in cirrhotic patients",
                    "criterion": "cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willingness to undergo fresh tumor biopsy at baseline if safe and feasible. Note: archival tissue may be used at baseline provided histologic diagnosis was made and sufficient tissue is available for NGS analysis.",
            "criterions": [
                {
                    "exact_snippets": "Willingness to undergo fresh tumor biopsy at baseline if safe and feasible",
                    "criterion": "willingness to undergo fresh tumor biopsy at baseline",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety and feasibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "archival tissue may be used at baseline provided histologic diagnosis was made and sufficient tissue is available for NGS analysis",
                    "criterion": "archival tissue at baseline",
                    "requirements": [
                        {
                            "requirement_type": "histologic diagnosis",
                            "expected_value": "made"
                        },
                        {
                            "requirement_type": "sufficient tissue for NGS analysis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal",
            "criterions": [
                {
                    "exact_snippets": "Renal",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine OR calculated* serum creatinine clearance (GFR can be used in place of creatinine or creatinine clearance) ≤ 1.5 x ULN OR ≥ 30 mL/min for participants with creatinine levels > 1.5 x institutional ULN *calculate serum creatinine clearance using the standard Coccroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ... ≤ 1.5 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated* serum creatinine clearance ... ≥ 30 mL/min for participants with creatinine levels > 1.5 x institutional ULN",
                    "criterion": "serum creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "for participants with creatinine levels > 1.5 x institutional ULN"
                        }
                    ]
                },
                {
                    "exact_snippets": "GFR can be used in place of creatinine or creatinine clearance",
                    "criterion": "glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "substitution",
                            "expected_value": "can be used in place of creatinine or creatinine clearance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NGS analysis must be requested from archival tissue or fresh biopsy (if applicable) as per standard of care. Foundation One CDX is the preferred platform. Prior NGS sequencing results (including from another platform) will be accepted if NGS sequencing was previously obtained (please see protocol).",
            "criterions": [
                {
                    "exact_snippets": "NGS analysis must be requested from archival tissue or fresh biopsy (if applicable) as per standard of care.",
                    "criterion": "NGS analysis request",
                    "requirements": [
                        {
                            "requirement_type": "requested_from",
                            "expected_value": [
                                "archival tissue",
                                "fresh biopsy"
                            ]
                        },
                        {
                            "requirement_type": "standard_of_care",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Foundation One CDX is the preferred platform.",
                    "criterion": "NGS analysis platform",
                    "requirements": [
                        {
                            "requirement_type": "preferred_platform",
                            "expected_value": "Foundation One CDX"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior NGS sequencing results (including from another platform) will be accepted if NGS sequencing was previously obtained",
                    "criterion": "prior NGS sequencing results",
                    "requirements": [
                        {
                            "requirement_type": "acceptance_of_prior_results",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No clinically significant encephalopathy (Also see exclusion criteria).",
            "criterions": [
                {
                    "exact_snippets": "No clinically significant encephalopathy",
                    "criterion": "encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "not clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1,000/mcL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1,000/mcL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use effective contraceptive measures. Men with female partners of childbearing potential must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of bevacizumab. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab to avoid exposing the embryo. See also the protocol for additional information.",
            "criterions": [
                {
                    "exact_snippets": "For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use effective contraceptive measures.",
                    "criterion": "contraceptive behavior (men)",
                    "requirements": [
                        {
                            "requirement_type": "agreement to remain abstinent or use effective contraception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Men with female partners of childbearing potential must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of bevacizumab.",
                    "criterion": "contraceptive behavior (men with female partners of childbearing potential)",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive method failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "% per year"
                            }
                        },
                        {
                            "requirement_type": "duration of contraceptive use",
                            "expected_value": [
                                "during the treatment period",
                                "for 6 months after the last dose of bevacizumab"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab to avoid exposing the embryo.",
                    "criterion": "contraceptive behavior (men with pregnant female partners)",
                    "requirements": [
                        {
                            "requirement_type": "abstinence or condom use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of contraceptive use",
                            "expected_value": [
                                "during the treatment period",
                                "for 6 months after the last dose of bevacizumab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Albumin ≥ 2.8 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Albumin ≥ 2.8 g/dL",
                    "criterion": "albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST (SGOT) and ALT (SGPT) ≤ 8 x ULN",
            "criterions": [
                {
                    "exact_snippets": "AST (SGOT) ... ≤ 8 x ULN",
                    "criterion": "AST (SGOT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT (SGPT) ... ≤ 8 x ULN",
                    "criterion": "ALT (SGPT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* As determined by the enrolling physician or protocol designee, ability of the subject to understand a written informed consent document, and ability and willingness to comply with study procedures for the entire length of the study. Patients with impaired decision-making capacity (IDMC) who have a close caregiver or legally authorized representative (LAR) and/or family member available are also eligible.",
            "criterions": [
                {
                    "exact_snippets": "ability of the subject to understand a written informed consent document",
                    "criterion": "ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ability and willingness to comply with study procedures for the entire length of the study",
                    "criterion": "ability and willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with impaired decision-making capacity (IDMC) who have a close caregiver or legally authorized representative (LAR) and/or family member available are also eligible",
                    "criterion": "impaired decision-making capacity with caregiver or LAR/family member available",
                    "requirements": [
                        {
                            "requirement_type": "impaired decision-making capacity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "caregiver or LAR/family member availability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients who have received prior immunotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior immunotherapy",
                    "criterion": "prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No requirement for concurrent concurrent antibiotics or antifungal agents for the prevention of opportunistic infection",
            "criterions": [
                {
                    "exact_snippets": "No requirement for concurrent concurrent antibiotics or antifungal agents for the prevention of opportunistic infection",
                    "criterion": "requirement for concurrent antibiotics or antifungal agents for prevention of opportunistic infection",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hemoptysis (< 2.5 mL of bright red blood per episode) within 1 month prior to study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of hemoptysis (< 2.5 mL of bright red blood per episode) within 1 month prior to study treatment.",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month"
                            }
                        },
                        {
                            "requirement_type": "amount_per_episode",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "mL"
                            }
                        },
                        {
                            "requirement_type": "blood_characteristic",
                            "expected_value": "bright red"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No stereotactic radiation or whole-brain radiation within 28 days prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "No stereotactic radiation ... within 28 days prior to randomization.",
                    "criterion": "stereotactic radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "No ... whole-brain radiation within 28 days prior to randomization.",
                    "criterion": "whole-brain radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with clinically meaningful encephalopathy, defined as a history of hepatic encephalopathy within 6 months prior to first dose of study treatment or requirement for medications to prevent or control encephalopathy (e.g. lactulose, rifaximin).",
            "criterions": [
                {
                    "exact_snippets": "history of hepatic encephalopathy within 6 months prior to first dose of study treatment",
                    "criterion": "hepatic encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for medications to prevent or control encephalopathy (e.g. lactulose, rifaximin)",
                    "criterion": "medication for encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "requirement_for_medication",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications in the opinion of the treating investigator.",
            "criterions": [
                {
                    "exact_snippets": "Any other disease ... that contraindicates the use of an investigational drug",
                    "criterion": "other disease",
                    "requirements": [
                        {
                            "requirement_type": "contraindication to investigational drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic dysfunction ... that contraindicates the use of an investigational drug",
                    "criterion": "metabolic dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "contraindication to investigational drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "physical examination finding ... that contraindicates the use of an investigational drug",
                    "criterion": "physical examination finding",
                    "requirements": [
                        {
                            "requirement_type": "contraindication to investigational drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical laboratory finding that contraindicates the use of an investigational drug",
                    "criterion": "clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "contraindication to investigational drug",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... may affect the interpretation of the results",
                    "criterion": "other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "affect interpretation of results",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding ... may render the patient at high risk from treatment complications in the opinion of the treating investigator",
                    "criterion": "other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding",
                    "requirements": [
                        {
                            "requirement_type": "high risk from treatment complications (per investigator)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have documented hepatitis virology status.",
            "criterions": [
                {
                    "exact_snippets": "documented hepatitis virology status",
                    "criterion": "hepatitis virology status",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No evidence of intracranial hemorrhage or spinal cord hemorrhage.",
            "criterions": [
                {
                    "exact_snippets": "No evidence of intracranial hemorrhage",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "No evidence of ... spinal cord hemorrhage",
                    "criterion": "spinal cord hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following additional high-risk features:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following additional high-risk features",
                    "criterion": "high-risk features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant traumatic injury within 4 weeks prior to start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Significant traumatic injury within 4 weeks prior to start of study treatment.",
                    "criterion": "significant traumatic injury",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment.",
                    "criterion": "treatment with a live, attenuated vaccine",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Core biopsy or other minor surgical procedure within 3 days prior to the first dose of bevacizumab.",
            "criterions": [
                {
                    "exact_snippets": "Core biopsy or other minor surgical procedure within 3 days prior to the first dose of bevacizumab.",
                    "criterion": "core biopsy or other minor surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to first dose of bevacizumab",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled tumor-related pain. NOTE: Patients requiring pain medication must be on a stable regimen at study entry.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled tumor-related pain",
                    "criterion": "tumor-related pain",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients requiring pain medication must be on a stable regimen at study entry",
                    "criterion": "pain medication regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with Type 1 diabetes mellitus on an insulin regimen are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Patients with Type 1 diabetes mellitus",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on an insulin regimen",
                    "criterion": "insulin regimen",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A stable regimen of highly active anti-retroviral therapy (HAART)",
            "criterions": [
                {
                    "exact_snippets": "A stable regimen of highly active anti-retroviral therapy (HAART)",
                    "criterion": "highly active anti-retroviral therapy (HAART) regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of inflammatory process within 6 months prior to start of study treatment including but not limited to active peptic ulcer disease, diverticulitis or colitis.",
            "criterions": [
                {
                    "exact_snippets": "History of inflammatory process within 6 months prior to start of study treatment",
                    "criterion": "inflammatory process",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "active peptic ulcer disease",
                    "criterion": "peptic ulcer disease",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "colitis",
                    "criterion": "colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 6 weeks must discontinue these medications prior to starting protocol therapy, with the exception of:",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 6 weeks must discontinue these medications prior to starting protocol therapy",
                    "criterion": "systemic immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within prior period",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "discontinuation prior to protocol therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L, calcium > 12 mg/dL or corrected serum calcium > ULN)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled or symptomatic hypercalcemia",
                    "criterion": "hypercalcemia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ionized calcium > 1.5 mmol/L",
                    "criterion": "ionized calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "mmol/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calcium > 12 mg/dL",
                    "criterion": "serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 12,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "corrected serum calcium > ULN",
                    "criterion": "corrected serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active autoimmune disease managed with systemic corticosteroids less than the equivalent of prednisone 10 mg daily.",
            "criterions": [
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "managed with systemic corticosteroids less than the equivalent of prednisone 10 mg daily",
                    "criterion": "systemic corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg prednisone daily"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active hepatitis B virus (HBV) infection must have a viral load < 500 IU/mL within 28 days prior to start of study treatment and be on suppressive therapy (per local standard of care) for a minimum of 14 days prior to start of study treatment and for the length of the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with active hepatitis B virus (HBV) infection",
                    "criterion": "active hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a viral load < 500 IU/mL within 28 days prior to start of study treatment",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 500,
                                "unit": "IU/mL"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to start of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "be on suppressive therapy (per local standard of care) for a minimum of 14 days prior to start of study treatment and for the length of the study",
                    "criterion": "suppressive therapy for HBV",
                    "requirements": [
                        {
                            "requirement_type": "duration prior to treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "duration during study",
                            "expected_value": "for the length of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with untreated/uncontrolled CNS/leptomeningeal disease. Note: Patients with asymptomatic, treated CNS disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy and the following criteria are met:",
            "criterions": [
                {
                    "exact_snippets": "Patients with untreated/uncontrolled CNS/leptomeningeal disease.",
                    "criterion": "CNS/leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with asymptomatic, treated CNS disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated"
                        },
                        {
                            "requirement_type": "immediate CNS specific treatment requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "CNS specific treatment requirement during first cycle",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of Coumadin-like products or full dose oral or parenteral anticoagulants. Use of prophylactic low dose anticoagulation, unfractionated heparin or LMWH is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Use of Coumadin-like products or full dose oral or parenteral anticoagulants.",
                    "criterion": "anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "Coumadin-like products",
                                "full dose oral anticoagulants",
                                "full dose parenteral anticoagulants"
                            ]
                        },
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of prophylactic low dose anticoagulation, unfractionated heparin or LMWH is allowed.",
                    "criterion": "anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "prophylactic low dose anticoagulation",
                                "unfractionated heparin",
                                "LMWH"
                            ]
                        },
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only are eligible provided: 1) rash covers < 10% of body surface area (BSA), 2) disease is well controlled at baseline and requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%).",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only",
                    "criterion": "eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rash covers < 10% of body surface area (BSA)",
                    "criterion": "rash body surface area coverage",
                    "requirements": [
                        {
                            "requirement_type": "coverage",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "% BSA"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "disease is well controlled at baseline",
                    "criterion": "disease control at baseline",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)",
                    "criterion": "topical steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "potency",
                            "expected_value": "low"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known human immunodeficiency virus (HIV) are allowed on study provided they have:",
            "criterions": [
                {
                    "exact_snippets": "Patients with known human immunodeficiency virus (HIV)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active tuberculosis",
            "criterions": [
                {
                    "exact_snippets": "Active tuberculosis",
                    "criterion": "tuberculosis",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A CD4 count above 250 cells/mcL",
            "criterions": [
                {
                    "exact_snippets": "A CD4 count above 250 cells/mcL",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "cells/mcL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of autoimmune hypothyroidism on thyroid replacement hormone are eligible.",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune hypothyroidism",
                    "criterion": "autoimmune hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on thyroid replacement hormone",
                    "criterion": "thyroid replacement hormone",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea)",
                    "criterion": "systemic immunosuppressant medication use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": "acute"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "low dose"
                        },
                        {
                            "requirement_type": "route",
                            "expected_value": "systemic"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with CD137 agonists",
                    "criterion": "prior treatment with CD137 agonists",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies",
                    "criterion": "prior treatment with immune checkpoint blockade therapies",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy types",
                            "expected_value": [
                                "anti-CTLA-4 therapeutic antibodies",
                                "anti-PD-1 therapeutic antibodies",
                                "anti-PD-L1 therapeutic antibodies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Metastatic disease that involves major airways or blood vessels. Patients with vascular invasion of the portal or hepatic veins may be enrolled.",
            "criterions": [
                {
                    "exact_snippets": "Metastatic disease that involves major airways or blood vessels.",
                    "criterion": "metastatic disease involving major airways or blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with vascular invasion of the portal or hepatic veins may be enrolled.",
                    "criterion": "vascular invasion of the portal or hepatic veins",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture within 30 days prior to start of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Serious, non-healing or dehiscing wound ... within 30 days prior to start of study treatment.",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "serious, non-healing or dehiscing"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to start of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "active ulcer ... within 30 days prior to start of study treatment.",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to start of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture within 30 days prior to start of study treatment.",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to start of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with serious active infection within 2 weeks prior to enrollment (e.g. requiring hospitalization and/or intravenous [IV] antibiotics) infection within 2 weeks prior to enrollment, or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible.",
            "criterions": [
                {
                    "exact_snippets": "serious active infection within 2 weeks prior to enrollment (e.g. requiring hospitalization and/or intravenous [IV] antibiotics)",
                    "criterion": "serious active infection",
                    "requirements": [
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        },
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "currently receiving oral or IV antibiotics for the treatment of infection",
                    "criterion": "current antibiotic treatment for infection",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "treatment of infection"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known concurrent malignancy that is expected to require active treatment within two years or may interfere with the interpretation of the efficacy and safety outcomes of this study in the opinion of the treating investigator. Note: Superficial bladder cancer, nonmelanoma skin cancers, and low-grade prostate cancer not requiring cytotoxic therapy should not exclude participation in this trial. Patients with CLL may be enrolled if they do not require active chemotherapy and their hematologic, renal and hepatic function meets criteria previously mentioned.",
            "criterions": [
                {
                    "exact_snippets": "known concurrent malignancy that is expected to require active treatment within two years",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "expected need for active treatment within two years",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "known concurrent malignancy that ... may interfere with the interpretation of the efficacy and safety outcomes of this study in the opinion of the treating investigator",
                    "criterion": "concurrent malignancy",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study outcome interpretation (in investigator's opinion)",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Superficial bladder cancer, nonmelanoma skin cancers, and low-grade prostate cancer not requiring cytotoxic therapy should not exclude participation",
                    "criterion": "superficial bladder cancer, nonmelanoma skin cancers, low-grade prostate cancer not requiring cytotoxic therapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from trial",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with CLL may be enrolled if they do not require active chemotherapy",
                    "criterion": "chronic lymphocytic leukemia (CLL)",
                    "requirements": [
                        {
                            "requirement_type": "requirement for active chemotherapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "their hematologic, renal and hepatic function meets criteria previously mentioned",
                    "criterion": "hematologic, renal and hepatic function (in CLL patients)",
                    "requirements": [
                        {
                            "requirement_type": "meets previously mentioned criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with active autoimmune disease requiring systemic corticosteroids greater than the equivalent of prednisone 10 mg daily or other systemic immunosuppressive medications including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, colitis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis, with the following exceptions:",
            "criterions": [
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring systemic corticosteroids greater than the equivalent of prednisone 10 mg daily",
                    "criterion": "systemic corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone equivalent daily"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring ... other systemic immunosuppressive medications",
                    "criterion": "systemic immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, colitis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis",
                    "criterion": "specific autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "systemic lupus erythematosus",
                                "rheumatoid arthritis",
                                "inflammatory bowel disease",
                                "colitis",
                                "vascular thrombosis associated with antiphospholipid syndrome",
                                "Wegener's granulomatosis",
                                "Sjögren's syndrome",
                                "Bell's palsy",
                                "Guillain-Barré syndrome",
                                "multiple sclerosis",
                                "autoimmune thyroid disease",
                                "vasculitis",
                                "glomerulonephritis"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment.",
                    "criterion": "symptomatic lesions amenable to palliative radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients should be recovered from the effects of radiation.",
                    "criterion": "recovery from effects of radiation",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant vascular disease (e.g. aortic aneurysm requiring surgical repair) or vasculitis within 6 months prior to initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Significant vascular disease (e.g. aortic aneurysm requiring surgical repair) ... within 6 months prior to initiation of study treatment.",
                    "criterion": "significant vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "vasculitis within 6 months prior to initiation of study treatment.",
                    "criterion": "vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "presence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An undetectable HIV viral load on standard PCR-based testing",
            "criterions": [
                {
                    "exact_snippets": "An undetectable HIV viral load on standard PCR-based testing",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "testing method",
                            "expected_value": "standard PCR-based testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received prior systemic therapy for HCC.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior systemic therapy for HCC",
                    "criterion": "prior systemic therapy for HCC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of intestinal obstruction. Note: Patients with previous intestinal obstruction may be enrolled if they have received definitive treatment for symptom resolution.",
            "criterions": [
                {
                    "exact_snippets": "History of intestinal obstruction",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with previous intestinal obstruction may be enrolled if they have received definitive treatment for symptom resolution",
                    "criterion": "intestinal obstruction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definitive treatment for symptom resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have undergone prior solid organ or bone marrow transplant with the exception of patients with prior renal transplant for whom dialysis may be employed in the event of graft rejection.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have undergone prior solid organ or bone marrow transplant",
                    "criterion": "history of prior transplant",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid organ",
                                "bone marrow"
                            ]
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "exception of patients with prior renal transplant for whom dialysis may be employed in the event of graft rejection",
                    "criterion": "history of prior renal transplant with possible dialysis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "renal"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dialysis in event of graft rejection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of intracranial hemorrhage within 1 month prior to study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of intracranial hemorrhage within 1 month prior to study treatment.",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologic diagnosis of fibrolamellar or sarcomatoid HCC or mixed cholangiocarcinoma-HCC.",
            "criterions": [
                {
                    "exact_snippets": "Histologic diagnosis of fibrolamellar ... HCC",
                    "criterion": "fibrolamellar HCC",
                    "requirements": [
                        {
                            "requirement_type": "histologic diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologic diagnosis of ... sarcomatoid HCC",
                    "criterion": "sarcomatoid HCC",
                    "requirements": [
                        {
                            "requirement_type": "histologic diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologic diagnosis of ... mixed cholangiocarcinoma-HCC",
                    "criterion": "mixed cholangiocarcinoma-HCC",
                    "requirements": [
                        {
                            "requirement_type": "histologic diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).",
            "criterions": [
                {
                    "exact_snippets": "Evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant coagulopathy (in the absence of therapeutic anticoagulation)",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "context",
                            "expected_value": "in the absence of therapeutic anticoagulation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months prior to initiation of study treatment. Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure.",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal or tracheoesophageal fistula ... within 6 months prior to initiation of study treatment",
                    "criterion": "abdominal or tracheoesophageal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal (GI) perforation ... within 6 months prior to initiation of study treatment",
                    "criterion": "gastrointestinal (GI) perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... intra-abdominal abscess within 6 months prior to initiation of study treatment",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure",
                    "criterion": "abdominal free air",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "explanation",
                            "expected_value": "not explained by paracentesis or recent surgical procedure"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of nephrotic or nephritic syndrome.",
            "criterions": [
                {
                    "exact_snippets": "History of nephrotic ... syndrome",
                    "criterion": "nephrotic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... nephritic syndrome",
                    "criterion": "nephritic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of arterial thrombotic event (e.g. myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack) within 6 months prior to initiation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of arterial thrombotic event (e.g. myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack) within 6 months prior to initiation of study treatment.",
                    "criterion": "arterial thrombotic event",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with clinically meaningful ascites, defined as ascites requiring non-pharmacologic intervention (e.g. paracentesis) to maintain symptomatic control within 3 months prior to the first dose of study treatment. Note: Patients with ascites meeting eligibility criteria who require pharmacologic intervention (e.g. diuretics) to maintain symptomatic control and who have been on stable doses of diuretics for 2 months prior to the first dose of study treatment are eligible.",
            "criterions": [
                {
                    "exact_snippets": "clinically meaningful ascites, defined as ascites requiring non-pharmacologic intervention (e.g. paracentesis) to maintain symptomatic control within 3 months prior to the first dose of study treatment",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically meaningful"
                        },
                        {
                            "requirement_type": "intervention_type",
                            "expected_value": "non-pharmacologic"
                        },
                        {
                            "requirement_type": "intervention_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to first dose of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites meeting eligibility criteria who require pharmacologic intervention (e.g. diuretics) to maintain symptomatic control and who have been on stable doses of diuretics for 2 months prior to the first dose of study treatment",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "intervention_type",
                            "expected_value": "pharmacologic"
                        },
                        {
                            "requirement_type": "intervention_stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months prior to first dose of study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* See protocol for a more comprehensive list of autoimmune diseases and immune deficiencies.",
            "criterions": [
                {
                    "exact_snippets": "autoimmune diseases",
                    "criterion": "autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "see protocol for details"
                        }
                    ]
                },
                {
                    "exact_snippets": "immune deficiencies",
                    "criterion": "immune deficiencies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "see protocol for details"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary embolism, portal vein thrombosis, or any other significant thromboembolism) must be on a stable dose of anticoagulation for 1 month prior to initiation of study treatment and must have completely treated varices.",
            "criterions": [
                {
                    "exact_snippets": "History of venous thromboembolic event (e.g. deep vein thrombosis, pulmonary embolism, portal vein thrombosis, or any other significant thromboembolism) must be on a stable dose of anticoagulation for 1 month prior to initiation of study treatment",
                    "criterion": "history of venous thromboembolic event",
                    "requirements": [
                        {
                            "requirement_type": "anticoagulation therapy stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have completely treated varices",
                    "criterion": "varices",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "completely treated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with co-infection with HBV and hepatitis C virus (HCV) are excluded. Patients with a history of HCV infection but with negative HCV RNA by PCR are considered non-infected with HCV.",
            "criterions": [
                {
                    "exact_snippets": "Patients with co-infection with HBV and hepatitis C virus (HCV) are excluded.",
                    "criterion": "co-infection with HBV and HCV",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a history of HCV infection but with negative HCV RNA by PCR are considered non-infected with HCV.",
                    "criterion": "HCV infection",
                    "requirements": [
                        {
                            "requirement_type": "history of infection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HCV RNA by PCR",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted.",
            "criterions": [
                {
                    "exact_snippets": "History of idiopathic pulmonary fibrosis",
                    "criterion": "idiopathic pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "organizing pneumonia (e.g., bronchiolitis obliterans)",
                    "criterion": "organizing pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "bronchiolitis obliterans",
                    "criterion": "bronchiolitis obliterans",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced pneumonitis",
                    "criterion": "drug-induced pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "idiopathic pneumonitis",
                    "criterion": "idiopathic pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of active pneumonitis on screening chest computed tomography (CT) scan",
                    "criterion": "active pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence_on_CT_scan",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chronic or recent (within 10 days of first dose of study treatment) use of aspirin > 325 mg/day, dipyramidaole, ticlopidine, clopidogrel, or dilostazol. Note: Use of aspirin < 325 mg/day is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Chronic or recent (within 10 days of first dose of study treatment) use of aspirin > 325 mg/day",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 325,
                                "unit": "mg/day"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic or recent (within 10 days of first dose of study treatment) use of ... dipyramidaole",
                    "criterion": "dipyridamole use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic or recent (within 10 days of first dose of study treatment) use of ... ticlopidine",
                    "criterion": "ticlopidine use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic or recent (within 10 days of first dose of study treatment) use of ... clopidogrel",
                    "criterion": "clopidogrel use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chronic or recent (within 10 days of first dose of study treatment) use of ... dilostazol",
                    "criterion": "cilostazol use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "chronicity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins or know hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab infusion.",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "criterion": "severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "know hypersensitivity to Chinese hamster ovary cell products",
                    "criterion": "hypersensitivity to Chinese hamster ovary cell products",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "know hypersensitivity ... to any component of the atezolizumab or bevacizumab infusion",
                    "criterion": "hypersensitivity to any component of the atezolizumab or bevacizumab infusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension defined as systolic pressure ≥ 150/90 in spite of maximum anti-hypertensive therapy.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension defined as systolic pressure ≥ 150/90 in spite of maximum anti-hypertensive therapy.",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic pressure ≥ 150/90",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in spite of maximum anti-hypertensive therapy",
                    "criterion": "anti-hypertensive therapy",
                    "requirements": [
                        {
                            "requirement_type": "therapy status",
                            "expected_value": "maximum"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension and adrenocortical insufficiency.",
            "criterions": [
                {
                    "exact_snippets": "use of inhaled corticosteroids",
                    "criterion": "inhaled corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use of ... mineralocorticoids (e.g., fludrocortisone)",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with orthostatic hypotension",
                    "criterion": "orthostatic hypotension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with ... adrenocortical insufficiency",
                    "criterion": "adrenocortical insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No evidence of interim progression between the completion of CNS-directed therapy and the start of study enrollment.",
            "criterions": [
                {
                    "exact_snippets": "No evidence of interim progression between the completion of CNS-directed therapy and the start of study enrollment.",
                    "criterion": "interim progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with uncontrolled intercurrent illness (e.g., including but not limited to uncontrolled HTN [systolic BP ≥ 150, diastolic BP ≥ 100 despite optimal medical management or history of hypertensive crisis or hypertensive encephalopathy], symptomatic congestive heart failure [CHF], uncontrolled cardiac arrhythmia, or other within 3 months prior to start of study treatment or psychiatric illness/social situations or other conditions that would limit compliance with study requirements or substantially increase risk of incurring AEs in the opinion of the treating investigator.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled intercurrent illness (e.g., including but not limited to uncontrolled HTN [systolic BP ≥ 150, diastolic BP ≥ 100 despite optimal medical management or history of hypertensive crisis or hypertensive encephalopathy]",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "response to medical management",
                            "expected_value": "despite optimal medical management"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "hypertensive crisis",
                                "hypertensive encephalopathy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure [CHF]",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "other within 3 months prior to start of study treatment",
                    "criterion": "other uncontrolled intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 3 months prior to start of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations or other conditions that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations or other conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                },
                {
                    "exact_snippets": "other conditions that would ... substantially increase risk of incurring AEs in the opinion of the treating investigator",
                    "criterion": "other conditions",
                    "requirements": [
                        {
                            "requirement_type": "risk of adverse events",
                            "expected_value": "substantially increase risk of incurring AEs in the opinion of the treating investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have had chemotherapy, definitive radiation, biological cancer therapy, or investigational agent/device within 21 days of first planned dose of study therapy (within 14 days for palliative radiation). Patients who have had major surgery within 4 weeks of start of study therapy or anticipation of need for a major surgical procedure during the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have had chemotherapy ... within 21 days of first planned dose of study therapy",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "definitive radiation ... within 21 days of first planned dose of study therapy",
                    "criterion": "definitive radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biological cancer therapy ... within 21 days of first planned dose of study therapy",
                    "criterion": "biological cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational agent/device within 21 days of first planned dose of study therapy",
                    "criterion": "investigational agent/device",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days for palliative radiation",
                    "criterion": "palliative radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have had major surgery within 4 weeks of start of study therapy",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of need for a major surgical procedure during the study",
                    "criterion": "anticipated need for major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need during study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of esophageal and/or gastric hemorrhage within 3 months prior to study treatment.",
            "criterions": [
                {
                    "exact_snippets": "History of esophageal and/or gastric hemorrhage within 3 months prior to study treatment.",
                    "criterion": "esophageal hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of esophageal and/or gastric hemorrhage within 3 months prior to study treatment.",
                    "criterion": "gastric hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to study treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled pleural effusion or pericardial effusion requiring frequent drainage procedures (> once monthly). Patients with indwelling catheters (e.g. PleurX®) are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled pleural effusion",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled ... pericardial effusion",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring frequent drainage procedures (> once monthly)",
                    "criterion": "effusion drainage frequency",
                    "requirements": [
                        {
                            "requirement_type": "frequency",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "per month"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > CTCAE Grade 1) with the exception of alopecia or neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > CTCAE Grade 1)",
                    "criterion": "recovery from adverse events due to prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "residual_toxicity_grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of alopecia or neuropathy",
                    "criterion": "residual toxicities of alopecia or neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "exemption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Note: Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD with appropriate management of varices (if applicable) within 6 months of prior to initiation of study treatment do not need to repeat the procedure.",
            "criterions": [
                {
                    "exact_snippets": "Patients with untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding",
                    "criterion": "esophageal and/or gastric varices",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "untreated",
                                "incompletely treated"
                            ]
                        },
                        {
                            "requirement_type": "bleeding status",
                            "expected_value": [
                                "with bleeding",
                                "high risk for bleeding"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients must undergo an esophagogastroduodenoscopy (EGD) ... all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment",
                    "criterion": "esophagogastroduodenoscopy (EGD)",
                    "requirements": [
                        {
                            "requirement_type": "procedure performed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment",
                    "criterion": "varices assessment and treatment",
                    "requirements": [
                        {
                            "requirement_type": "assessment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment per local standard of care",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have undergone an EGD with appropriate management of varices (if applicable) within 6 months of prior to initiation of study treatment do not need to repeat the procedure",
                    "criterion": "EGD with appropriate management of varices",
                    "requirements": [
                        {
                            "requirement_type": "procedure performed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to initiation of study treatment"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Subject must meet all of the following applicable inclusion criteria to participate in this study:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Subjects meeting any of the criteria below may not participate in the study:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}